

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

Olerup SSP[®] DR low resolution screening

Product number:	101.103-48/12 – including <i>Taq</i> pol. 101.103-48u/12u – without <i>Taq</i> pol.
Lot number:	9L6
Expiry date:	2025-06-01
Number of tests:	48 tests – Product No. 101.103-48/48u 12 tests – Product No. 101.103-12/12u
Number of wells per test:	23 + 1
Storage - pre-aliquoted primers:	dark at -20°C
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

This Product Description is only valid for Lot No. 9L6.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP[®] DR LOW RESOLUTION LOT (3L6)

- The product documentation has been updated for new alleles of IMGT 3.44.0.
- The kit resolution focuses on common and well documented (CWD) alleles¹.

¹As described in section Uniquely Identified Alleles.

The **DR low resolution screening** primer set, specificity and interpretation tables have been updated for the DRB alleles described since the previous *Olerup SSP[®]* DR low resolution screening lot was made (**Lot No. 3L6**).

The primers of the wells detailed below have been exchanged, modified or added compared to the previous lot. (**Lot No. 3L6**).

Well	5'-primer	3'-primer	rationale
11	-	Modified	3'-primers optimized for better yield.
12	-	Exchanged, removed	3'-primer exchanged for the DRB1*10:29 allele. 3'-primer removed for the DRB1*03:126 allele.
18	-	Exchanged	3'-primer exchanged for reducing tendency of primer oligomer formation.

¹S. J. Mack, P. Cano, J. A. Hollenbach et al.
Common and well-documented HLA alleles: 2012 update to the CWD catalogue. Tissue Antigens, 2013, 81, 194–203



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

Well **24** contains Negative Control primer pairs, that will amplify the majority of the Olerup SSP[®] HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
5'-primer¹	164	340	440	45	45	43	36
	5'-CAC3'	5'-Agg3'	5'-TTA3'	5'-Tgg3'	5'-Tgg3'	5'-Tgg3'	5'-TAC3'
							36
							5'-TAT3'
3'-primer²	231	2nd I	507	59	58	57	47
	5'-TgC3'	5'-AAA3'	5'-TTg3'	5'-CTC3'	5'-ggC3'	5'-CTC3'	5'-ACA3'
							48
							5'-gCA3'
							48
							5'-gCC3'
							52
							5'-TgT3'
A*	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For In Vitro Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

PRODUCT DESCRIPTION

DR low resolution screening

CONTENT

The primer set contains 5'- and 3'-primers for grouping the DRB1*01:01 to DRB1*10:40 alleles into the corresponding serological groups DR1 to DR18 as well as primer pairs for recognizing the DRB3, DRB4 and DRB5 groups of alleles.

PLATE LAYOUT

Each test consists of 24 PCR reactions in a 24 well cut PCR plate.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	NC

The 24 well cut PCR plate is marked with ‘DR low screening’ in silver/gray ink.
Well No. 1 is marked with the Lot No. ‘9L6’.

Wells 1 to 23 – DR low resolution screening primers.

Well 24 – Negative Control.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

Please note: When removing each 24 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

Only HLA-DRB alleles will be amplified by the 23 wells of the DR low resolution screening primer set, **wells 1 to 23**. Thus, the interpretation of DR low resolution screening typings is not influenced by other HLA class II genes.

UNIQUELY IDENTIFIED ALLELES

All the HLA-DRB1, -DRB3, -DRB4 and -DRB5 alleles, i.e. **DRB1*01:01:01:01 to DRB1*10:40**, **DRB3*01:01:02:01 to DRB3*03:52**, **DRB4*01:01:01:01 to DRB4*03:01N**, **DRB5*01:01:01:01 to DRB5*02:30**, recognized by the HLA Nomenclature Committee in April 2021^{1,2} will be amplified by the primers in the DR low resolution screening SSP kit. The HLA-DRB alleles will be grouped into their corresponding serological specificities.



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

The following alleles give rise to identical amplification patterns with the DR low resolution screening primer set. These alleles can be separated by the respective high resolution primer sets.

Alleles	Alleles
DRB1*03:126, 13:193	DRB1*11:264, 13:05:01:01-13:05:03, 13:07:01-13:07:02, 13:11:01-13:11:02, 13:14:01-13:14:03, 13:21:01:01-13:21:02, 13:42:01-13:42:02, 13:46, 13:49-13:50:03, 13:62, 13:100, 13:108, 13:132, 13:136, 13:150, 13:169, 13:189, 13:199, 13:203, 13:229, 13:246, 13:284, 13:302
DRB1*08:09:02, 14:15	DRB1*12:57, DRB3*02:111
DRB1*08:20, 13:18, 13:47, 13:55, 13:158, 13:164, 13:232, 13:286	DRB1*13:13, 13:119, 13:154, 13:156, 14:84, 14:116, 14:144
DRB1*08:31, 11:05, 11:209	DRB1*13:44, 13:86, 13:206, 14:183
DRB1*08:41, 08:75, 11:67, 11:193:01-11:193:02	DRB1*13:235, 14:98

¹DRB alleles listed on the IMGT/HLA web page 2021-April-20, release 3.44.0, www.ebi.ac.uk/imgt/hla.

²Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

SPECIFICITY TABLE

DR low resolution screening primer set

Specificities and sizes of the PCR products of the 23+1 primer mixes of the DR low resolution screening primer set

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	DR serology ³	Amplified HLA-DRB ⁴ alleles
1⁶	210 bp, 235 bp, 260 bp	515 bp	1	*01:01:01:01-01:02:13, 01:04-01:38, 01:40N-01:98, 01:100-01:101, 01:103-01:111, 01:113-01:122
2	200 bp	430 bp	1/103	*01:03:01-01:03:05, 01:39N, 01:42, 01:61, 01:89, 01:99, 01:102, 01:112
3^{6,7,8}	200 bp, 230 bp	430 bp	2, 15	*15:01:01:01-15:192, 16:66
4⁷	210 bp	430 bp	11, 16	*11:30, 12:57, 16:01:01-16:05:02, 16:07-16:69, DRB3*02:111
5^{5,11}	125 bp, 225 bp	515 bp	3, 11, 13, 17, 18	*03:01:01:01-03:11:01, 03:11:03-03:125, 03:127-03:182, 11:07:01-11:07:02, 11:27:02-11:27:03, 11:84:02-11:84:03, 11:103:01-11:103:02, 11:105, 11:107, 11:124:02-11:125, 11:136, 11:173, 13:33:01, 13:61:02, 13:94:01, 13:96:01, 14:38:02, 14:104, 14:111, 14:171, 15:25, 15:37:01, 15:100, 15:104:01, DRB3*02:146
6^{5,11}	75 bp, 205 bp	430 bp	3, 6, 11, 13, 14, 17	*03:01:01:01-03:01:23, 03:01:25-03:01:33, 03:04:01-03:06, 03:08-03:11:01, 03:11:03-03:16, 03:18-03:20, 03:22-03:23, 03:25:01-03:26, 03:28, 03:30-03:31, 03:33-03:34, 03:36-03:37, 03:43-03:48, 03:50-03:52:02, 03:54-03:68N, 03:70-03:73, 03:75-03:86, 03:89, 03:91-03:93, 03:95-03:96, 03:98-03:100:02, 03:104, 03:106-03:114, 03:116-03:118, 03:121-03:130, 03:132-03:149, 03:151-03:153, 03:156N-03:166, 03:168-03:170, 03:172, 03:174N-03:175, 03:177, 03:180-03:182, 08:40, 08:92, 11:02:01:01-11:03:04, 11:11:01, 11:11:03, 11:14:01:01-11:14:02, 11:16:01:01-11:16:01:02, 11:20-11:21, 11:36, 11:40-11:41, 11:48, 11:59, 11:63:01-11:63:02, 11:65:01-11:65:02, 11:68, 11:70, 11:73, 11:76, 11:79-11:80, 11:83, 11:85-11:87, 11:93, 11:118:01-11:118:02, 11:122, 11:124:01-11:124:02, 11:127, 11:131-11:132, 11:135, 11:138-11:139, 11:142, 11:151, 11:153, 11:161, 11:168, 11:171, 11:176, 11:182, 11:184, 11:213, 11:229, 11:231, 11:233, 11:237, 11:241-11:242, 11:251, 11:256, 11:260, 11:270, 11:276,



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

				12:73, 13:01:01:01-13:02:01:10, 13:02:02 [?] , 13:02:03-13:04, 13:08, 13:10, 13:15-13:17, 13:19-13:20:01:03, 13:22:01:01-13:24:01:03, 13:27:01-13:29:01:02, 13:31-13:41, 13:43, 13:45, 13:48, 13:51-13:54, 13:57, 13:59, 13:61:01-13:61:02, 13:63-13:66:02, 13:68- 13:76, 13:78-13:81, 13:83-13:85, 13:87-13:99, 13:101-13:102, 13:104-13:107, 13:109, 13:110 [?] , 13:111-13:117:01:02, 13:120-13:131, 13:133, 13:135, 13:137N-13:145, 13:147- 13:149, 13:151-13:153, 13:155, 13:159, 13:162, 13:165-13:166, 13:167 [?] , 13:168, 13:170-13:180, 13:182-13:188, 13:190- 13:191, 13:193-13:194, 13:196, 13:198, 13:200N-13:202, 13:204-13:205, 13:207- 13:209, 13:212-13:219, 13:221, 13:223, 13:225-13:227, 13:230, 13:233-13:234, 13:236-13:245, 13:247-13:283, 13:285, 13:287-13:288, 13:289N [?] , 13:290-13:294, 13:296-13:301, 13:303-13:312, 14:16, 14:19, 14:21, 14:45, 14:82, 14:95, 14:109, 14:120, 14:122, 14:132, 14:178-14:179
7 ⁵	85 bp, 210 bp	430 bp	3, 6, 11, 13, 14, 1403, 18	*03:02:01:01-03:03, 03:27, 03:29, 03:38, 03:53, 03:74, 03:88, 03:90, 03:102-03:103, 03:115, 03:119, 03:126, 03:131, 03:154, 03:167, 03:176-03:177, 03:179, 11:13:01 ^w - 11:13:02 ^w , 11:26, 11:34, 11:267, 13:15, 13:19, 13:26:01-13:26:02, 13:44, 13:53, 13:57, 13:85-13:86, 13:104, 13:193, 13:198, 13:206, 13:235, 14:02:01:01-14:03:02, 14:06:01- 14:06:06, 14:09, 14:12:01-14:13, 14:17-14:21, 14:24, 14:27:01-14:27:02, 14:29-14:30, 14:32:01 ^w -14:32:02 ^w , 14:33, 14:40-14:41, 14:47-14:49, 14:51, 14:63, 14:65 ^w , 14:67, 14:77-14:78, 14:80-14:81, 14:83, 14:85, 14:89, 14:94, 14:98, 14:102, 14:106, 14:108- 14:109, 14:115, 14:119, 14:121, 14:135, 14:146, 14:154, 14:156, 14:159-14:160, 14:165, 14:170, 14:174, 14:176-14:177, 14:179, 14:181, 14:183, 14:194-14:195N, 14:198, 14:200, 14:209, 14:212, 14:218, 14:221-14:223, 14:226
8 ⁵	100 bp, 175 bp	430 bp	3, 4	*04:01:01:01-04:05:11, 04:05:13-04:321
9 ⁷	170 bp, 210 bp, 235 bp	430 bp	7, 13, 14	*07:01:01:01-07:01:01:02, 07:01:01:04- 07:01:25, 07:03-07:123, 08:67, 08:92, 10:11, 11:229, 11:270, 12:22, 12:73, 12:88, 13:17, 13:116, 13:175, 13:214, 14:50
10 ⁵	85 bp, 120 bp, 215 bp, 250 bp	515 bp	7, 8, 14	*07:06, 08:01:01-08:01:02, 08:01:04-08:19, 08:21-08:30:03, 08:32-08:56, 08:58-08:66, 08:68:01-08:79, 08:81-08:97, 08:99-08:106, 11:67, 11:193:01-11:193:02,



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

				12:16:01-12:16:03, 12:22, 12:39, 13:171:01, 13:197, 14:15, 14:68:01-14:68:02, 14:93
11^{5,8,12}	85 bp, 100 bp, 135 bp, 160 bp, 190 bp	430 bp	3, 9, 11	*03:08, 03:65, 03:140, 09:01:02:01-09:45, 11:07:01-11:07:02, 11:103:01-11:103:02, 11:105, 11:107, 11:125, 11:173, DRB3*01:42
12⁵	70 bp, 175 bp	430 bp	10, 11, 13	*03:76, 03:125, 03:174N, 10:01:01:01, 10:01:01:03-10:40, 11:59, 11:80, 11:83, 11:87, 11:135, 11:142, 11:182, 13:27:01-13:27:02, 13:41, 13:71, 13:129, 13:176, 13:277, 14:179
13⁵	100 bp, 175 bp	430 bp	3, 8, 11, 13, 14	*03:08, 03:65, 03:140, 08:31, 08:41, 08:63, 08:75, 11:01:01:01, 11:01:01:03-11:11:01, 11:11:03-11:70, 11:72-11:263, 11:265-11:282
14⁵	90 bp, 110 bp	430 bp	12, 14	*08:32, 08:53, 08:87, 12:01:01:01-12:56, 12:58-12:89, 14:52
15¹²	220 bp	430 bp	6, 8, 11, 13, 14, 1403	*03:76, 03:125, 03:174N, 08:20-08:21, 11:01:01:01, 11:01:01:03-11:01:27, 11:01:28 [?] , 11:01:29-11:04:22, 11:06:01-11:06:03, 11:08:01-11:11:01, 11:11:03-11:12:03, 11:14:01:01-11:16:01:02, 11:18-11:21, 11:23:01-11:25, 11:27:01-11:33, 11:35-11:51, 11:54:01-11:54:02, 11:56-11:66:02, 11:68, 11:70, 11:72-11:81, 11:83-11:88, 11:90-11:97, 11:99-11:102:02, 11:106, 11:108-11:124:02, 11:126-11:135, 11:137-11:142, 11:144-11:158, 11:160-11:172, 11:174-11:192, 11:194:01-11:201, 11:203-11:208, 11:210-11:228, 11:230-11:260, 11:262-11:265, 11:268-11:269, 11:271-11:282, 12:57, 13:01:01:01-13:02:01:10, 13:02:03-13:08, 13:10-13:16:01:02, 13:18-13:43, 13:45-13:85, 13:87-13:115, 13:117:01:01-13:128, 13:130-13:145, 13:147-13:174, 13:176-13:182, 13:184-13:191, 13:194-13:205, 13:207-13:209, 13:212-13:213, 13:215-13:221, 13:223-13:247, 13:249N-13:288, 13:289N [?] , 13:290-13:298N, 13:300-13:312, 14:03:01-14:03:02, 14:12:01-14:12:02, 14:16, 14:19, 14:21-14:22, 14:25:01-14:25:02, 14:27:01-14:27:02, 14:40, 14:53, 14:63, 14:67, 14:69, 14:74, 14:77-14:78, 14:84-14:85, 14:98, 14:102, 14:105, 14:109, 14:115-14:116, 14:128, 14:135, 14:144, 14:156, 14:173-14:174, 14:181, 14:218, 14:222N-14:223, DRB3*02:27, DRB3*02:111, DRB3*02:131, DRB3*02:160
16⁶	195 bp, 225 bp	430 bp	6, 8, 11, 12, 13, 14	*03:125, 08:01:01-08:01:02, 08:01:04-08:01:05, 08:01:07-08:02:04, 08:04:01-08:09:02, 08:11:01:01-08:11:01:02, 08:16-08:17, 08:20-08:22, 08:24:01-08:24:02, 08:26, 08:28, 08:31, 08:39, 08:41-08:44, 08:50,



0197

For In Vitro Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

08:52, 08:54-08:55, 08:57, 08:59, 08:64,
08:67, 08:70, 08:72-08:73, 08:75, 08:77-
08:80, 08:82-08:90, 08:92-08:94, 08:96,
08:98-08:101, 08:103, 08:105-08:106,
11:01:01:01, 11:01:01:03-11:01:17, 11:01:20-
11:04:20, 11:04:22-11:06:03, 11:09:01:01-
11:11:01, 11:11:03-11:12:03, 11:14:01:01-
11:16:01:02, 11:20-11:21, 11:23:01-11:25,
11:27:01-11:30, 11:32-11:33, 11:35-11:41,
11:43:01:01-11:44, 11:46:01-11:51, 11:54:01-
11:56, 11:58:01-11:63:02, 11:65:01-11:70,
11:72, 11:74:01-11:78, 11:80-11:88, 11:90-
11:97, 11:99-11:102:02, 11:106, 11:108-
11:118:02, 11:120-11:124:02, 11:126-11:129,
11:133-11:135, 11:137-11:142, 11:144-
11:152, 11:154-11:158, 11:160-11:172,
11:174-11:183, 11:185-11:190, 11:192-
11:201, 11:203-11:247, 11:249-11:260,
11:262-11:265, 11:269-11:279, 11:281-
11:282, 12:02:01:01-12:02:11, 12:13, 12:15-
12:16:03, 12:18-12:21, 12:23, 12:26-12:27,
12:31N-12:33, 12:37, 12:42-12:45, 12:49-
12:52, 12:55-12:57, 12:60N-12:61, 12:64-
12:65, 12:67, 12:69, 12:71, 12:73-12:76,
12:78, 12:80-12:81, 12:85, 13:01:01:01-
13:02:01:10, 13:02:03-13:02:18, 13:04-
13:05:03, 13:07:01-13:09, 13:11:01-13:11:02,
13:14:01-13:24:01:03, 13:26:01-13:29:01:02,
13:31-13:32, 13:34-13:36, 13:38-13:43, 13:45-
13:55, 13:57, 13:59, 13:61:01-13:65, 13:67-
13:76, 13:78-13:80, 13:83-13:84, 13:87,
13:91-13:93, 13:96:01-13:100, 13:102-13:109,
13:111-13:114, 13:116-13:117:01:02, 13:121,
13:123-13:132, 13:135-13:136, 13:138-
13:150, 13:153, 13:155, 13:158-13:160,
13:162, 13:164-13:166, 13:168-13:169,
13:171:01-13:171:02, 13:173, 13:175, 13:177,
13:179, 13:182-13:187, 13:189-13:192,
13:195, 13:197-13:205, 13:207-13:215,
13:217-13:218, 13:221-13:223, 13:225-
13:226, 13:229-13:230, 13:232-13:234,
13:236-13:252N, 13:254-13:288, 13:290-
13:294, 13:296-13:298N, 13:300-13:312,
14:15-14:16, 14:22, 14:24-14:25:02, 14:27:01-
14:27:02, 14:37, 14:53, 14:73, 14:105,
14:128, 14:226, **DRB3*02:111, DRB3*02:160**



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

17 ¹¹	175 bp, 240 bp	430 bp	3, 4, 6, 8, 11, 13, 14, 1403, 1404, 17, 18	*03:01:01:01-03:01:05, 03:01:07-03:01:08, 03:01:10-03:07:02, 03:09, 03:11:01, 03:11:03- 03:41:02, 03:43-03:45, 03:47-03:63, 03:66- 03:68N, 03:70-03:86, 03:88-03:91, 03:93- 03:110, 03:112-03:129, 03:131-03:139, 03:141-03:155, 03:157-03:161, 03:163- 03:172, 03:174N-03:182, 08:09:02, 08:20, 11:03:04, 11:04:17, 11:13:01-11:13:02, 11:17, 11:149, 11:202, 11:264, 12:20, 13:01:01:01- 13:16:01:02, 13:18-13:42:02, 13:44, 13:46- 13:66:02, 13:68-13:102, 13:104-13:115, 13:117:01:01-13:121, 13:123-13:158, 13:161- 13:164, 13:166-13:170, 13:171:02-13:174, 13:176-13:178, 13:180-13:190, 13:192- 13:194, 13:196, 13:198-13:213, 13:215- 13:216, 13:218-13:227, 13:229-13:247, 13:249N-13:298N, 13:300-13:312, 14:01:01, 14:01:02 [?] -14:01:04 [?] , 14:01:05-14:04:01:03, 14:04:02 [?] -14:04:03 [?] , 14:04:04-14:04:06, 14:04:09-14:21, 14:22 [?] , 14:23:01:01- 14:23:01:03, 14:23:02 [?] , 14:23:03-14:24, 14:25:01 [?] -14:26 [?] , 14:27:01-14:27:02, 14:28 [?] , 14:29-14:30, 14:31 [?] -14:32:03 [?] , 14:33, 14:34 [?] - 14:35 [?] , 14:36-14:37, 14:38:01 [?] -14:39 [?] , 14:40- 14:45, 14:47-14:48, 14:49 [?] -14:50 [?] , 14:51, 14:52 [?] , 14:54:01:01-14:54:06, 14:54:08- 14:54:10, 14:55 [?] , 14:56-14:57, 14:58 [?] , 14:59, 14:60 [?] -14:62 [?] , 14:63-14:65, 14:67, 14:68:01 [?] - 14:69 [?] , 14:70, 14:71 [?] -14:76 [?] , 14:77-14:78, 14:79 [?] , 14:80-14:85, 14:86 [?] -14:88 [?] , 14:89, 14:90 [?] , 14:91, 14:92N [?] -14:93 [?] , 14:94-14:96, 14:97 [?] , 14:98, 14:99 [?] , 14:100, 14:101 [?] , 14:102-14:103, 14:104 [?] -14:105 [?] , 14:106, 14:107 [?] , 14:108-14:109, 14:110 [?] , 14:111, 14:112 [?] -14:114 [?] , 14:115-14:116, 14:117 [?] - 14:120 [?] , 14:121, 14:122 [?] , 14:123, 14:124 [?] - 14:126:02 [?] , 14:127:01-14:127:02, 14:128 [?] - 14:133 [?] , 14:134-14:137N, 14:138 [?] -14:140 [?] , 14:141, 14:142 [?] -14:143 [?] , 14:144, 14:145 [?] - 14:151 [?] , 14:152N, 14:153 [?] , 14:154-14:156, 14:157 [?] -14:158 [?] , 14:159-14:162, 14:163 [?] - 14:164 [?] , 14:165, 14:166N [?] , 14:167, 14:168 [?] , 14:169-14:171, 14:172 [?] -14:173 [?] , 14:174, 14:175 [?] , 14:176-14:177, 14:178 [?] , 14:179, 14:180 [?] , 14:181, 14:182 [?] , 14:183, 14:184 [?] - 14:186 [?] , 14:187-14:188N, 14:189 [?] -14:190 [?] , 14:191-14:199, 14:201-14:202, 14:203 [?] , 14:204-14:207, 14:209-14:219, 14:220 [?] , 14:221, 14:222N [?] , 14:223-14:224, 14:225 [?] , 14:226-14:228, 14:229 [?] , 14:230-14:231N
------------------	-------------------	--------	--	---



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

18^{5,10}	85 bp, 140 bp, 180 bp, 240 bp	430 bp	4, 6, 8, 13, 14, 1404	*04:62, 04:69, 04:73:01-04:73:02, 04:105:01- 04:105:02, 04:122, 04:146, 04:162, 04:251, 04:284, 08:08, 11:69, 11:82, 11:88, 13:45, 13:197, 14:01:01-14:01:02, 14:01:04- 14:01:05, 14:04:01:01-14:04:09, 14:07:01- 14:07:02, 14:10:01:01-14:10:01:02, 14:16, 14:22, 14:25:01-14:26, 14:28, 14:31-14:32:03, 14:35, 14:37-14:39, 14:49-14:50, 14:53- 14:54:01:12, 14:54:03-14:55, 14:57-14:58, 14:60-14:62, 14:68:01-14:71, 14:73-14:76, 14:79, 14:82, 14:86-14:88, 14:90, 14:93, 14:99, 14:101, 14:104-14:105, 14:107, 14:110-14:114, 14:117-14:120, 14:122, 14:124-14:125, 14:128-14:129, 14:131, 14:137N-14:140, 14:142-14:143, 14:145- 14:147, 14:149-14:153, 14:157-14:158, 14:163-14:164, 14:166N, 14:168 ^w , 14:171- 14:173, 14:178, 14:180, 14:182, 14:184, 14:186, 14:189-14:192, 14:196-14:197N, 14:199, 14:201-14:205, 14:207-14:208, 14:210Q, 14:213-14:217, 14:219-14:220, 14:224-14:225, 14:227-14:231N, 15:167, DRB4*01:03:01:02N, DRB4*01:03:01:13N, DRB4*01:14N
19^{5,6,9}	110 bp, 145 bp, 170 bp	430 bp	3, 4, 6, 9, 11, 13, 14, 1404	*03:10, 03:126, 03:177, 04:211, 09:01:02:01- 09:01:05, 09:01:07-09:02:02, 09:04-09:22, 09:24-09:28, 09:30-09:45, 11:13:01-11:13:02, 11:17, 11:52, 11:202, 12:66, 13:43, 13:159, 13:171:01, 13:179, 13:191, 13:193, 13:217, 14:01:01-14:02:09, 14:04:01:01-14:11:01:02, 14:13-14:14, 14:16-14:18, 14:19 ^w , 14:20, 14:21 ^w , 14:22-14:23:04, 14:26, 14:28-14:36, 14:38:01-14:39, 14:41, 14:43-14:52, 14:54:01:01-14:54:03, 14:54:04 ^w , 14:54:05- 14:57, 14:59-14:62, 14:64-14:65, 14:68:01- 14:68:02, 14:70-14:76, 14:79-14:83, 14:86- 14:88, 14:90-14:97, 14:99-14:101, 14:103- 14:108, 14:109 ^w , 14:110-14:114, 14:117- 14:127:02, 14:129-14:134, 14:137N-14:140, 14:142-14:143, 14:145-14:155, 14:157- 14:160, 14:162-14:173, 14:175-14:180, 14:182, 14:184-14:185, 14:187-14:207, 14:209-14:217, 14:219-14:221, 14:224- 14:225, 14:227-14:231N, 15:27, 15:34, 15:54, 15:66:01-15:66:02, 15:122, 15:158, 15:187
20^{5,13}	110 bp, 150 bp, 180 bp, 220 bp	430 bp	2, 3, 4, 6, 8, 11, 13, 14, 1403, 1404, 16	*03:10, 03:157, 08:03:11 ^w , 08:09:01-08:09:02, 08:20-08:21, 08:32, 08:35, 08:36:02, 08:53, 08:68:01 ^w , 08:70 ^w , 08:87 ^w , 11:13:01-11:13:02, 11:17, 11:23:01-11:23:02, 11:25, 11:31, 11:45, 11:52, 11:55, 11:64, 11:89, 11:96, 11:119, 11:148, 11:159, 11:202, 11:266, 13:13, 13:18, 13:43, 13:45, 13:47, 13:55, 13:119, 13:144, 13:146, 13:154, 13:156, 13:158-13:159, 13:164, 13:171:01, 13:179,



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

				13:191, 13:197, 13:217, 13:232, 13:286, 14:01:01-14:01:05, 14:03:01-14:05:05, 14:07:01-14:08, 14:10:01:01-14:12:02, 14:14- 14:16, 14:18, 14:22-14:23:04, 14:25:01-14:28, 14:31-14:32:03, 14:34-14:36, 14:38:01-14:40, 14:42-14:45, 14:49-14:50, 14:53-14:65, 14:67- 14:79, 14:81-14:82, 14:84-14:93, 14:95-14:97, 14:99-14:105, 14:107, 14:110-14:120, 14:122- 14:140, 14:142-14:158, 14:160-14:164, 14:166N-14:169, 14:171-14:175, 14:178, 14:180-14:182, 14:184-14:193, 14:196- 14:197N, 14:199-14:208, 14:210Q-14:211, 14:213-14:220, 14:222N-14:225, 14:227- 14:231N, 15:21 ^w , 15:158 ^w , 15:187 ^w , 16:04:01 ^w -16:04:02 ^w , 16:18 ^w , DRB3*02:131, DRB4*01:31
21^{5,7,11,12}	90 bp, 160 bp, 190 bp, 240 bp	515 bp	12, 52	*12:05, 12:15, 12:57, 14:141, DRB3*01:01:02:01-01:97N, DRB3*02:01- 02:130, DRB3*02:132-02:161, DRB3*03:01:01:01-03:52
22^{6,10,13}	130 bp, 210 bp	430 bp	53	*10:19, 14:217, 15:141, DRB4*01:01:01:01, DRB4*01:01:01:03-01:146, DRB4*02:01N, DRB4*03:01N
23	175 bp, 215 bp	430 bp	51	DRB5*01:01:01:01-01:109, DRB5*02:02:01- 02:30
24¹⁴	-	-		Negative control

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of DR low resolution screening SSP subtypings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers, e.g. the primers in wells 3, 18, 19 and 20.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 430 or 515 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the longer, 515 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: 9L6

Lot-specific information

³The serological reactivity of all DRB alleles is not known. In this table we use the information in the HLA Dictionary 2004 on the www.ebi.ac.uk/imgt/hla web site and the expert-assigned serological grouping in Tissue Antigens (2009) 73:95-170.

⁴For several DRB alleles 1st and/or 3rd exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

⁵HLA-specific PCR products shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR products.

⁶Primer mixes 1, 3, 16, 19 and 22 have a tendency to giving rise to primer oligomer formation.

⁷Primer mixes 3, 4, 9 and 21 may have tendencies of unspecific amplification.

⁸Primer mixes 3 and 11 may give rise to a lower yield of HLA-specific PCR product than the other DR low primer mixes.

⁹Primer mix 19 has a tendency of primer oligomer formation and also has an intense primer cloud due to the high number of primers present in the primer mix.

¹⁰The DRB4*01:03:01:02N allele is amplified by the primer pairs in wells 18 and 22, whereas the DRB4*02:01N and DRB4*03:01N null alleles are only amplified by the primer pairs in well 22.

¹¹Due to sharing of sequence motifs in codon 38 and 47, DRB3*01:14 will also be amplified in primer mixes 5, 6, 17, and DRB3*01:23 and *02:32 will be amplified in primer mix 5, in addition to primer mix 21.

¹²Due to sharing of sequence motifs, DRB3*02:27 is amplified by the primer pairs in well 15, and DRB3*01:42 is amplified by the primer pairs in well 11, in addition to primer mix 21.

¹³Due to sharing of sequence motifs, DRB4*01:31 is amplified by the primer pairs in well 20 in addition to primer mix 22.

¹⁴Primer mix 24 contains a negative control, which will amplify the majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

Abbreviations

w: might be weakly amplified.

?: nucleotide sequence of the primer matching region not known.



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

PRIMER SPECIFICATION

Well No.	1	2	3	4	5	6	7	8	9	10	11	12
Length of spec.	210	200	200	210	125	75	85	100	170	85	85	70
PCR product	235		230		225	205	210	175	210	120	100	175
	260								235	215	135	
										250	160	
											190	
Length of int.	515	430	430	430	515	430	430	430	430	515	430	430
pos. control ¹												
5'-primer(s) ²	13(124) 5'-A.T 3'	14(129) 5'-gAA 3'	12(121) 5'-CTg 3'	11(119) 5'-gCT 3'	13(125) 5'-gTC 3'	12(122) 5'-TAC 3'	13(125) 5'-gTC 3'	13(124) 5'-AAC 3'	11(118) 5'-AgA 3'	16(133) 5'-gTT 3'	26(165) 5'-TAT 3'	26(164) 5'-gTA 3'
	14(129) 5'-gAA 3'		13(126) 5'-Agg 3'	13(126) 5'-Agg 3'	47(227) 5'-gTT 3'	13(125) 5'-gTC 3'		13(125) 5'-ATA 3'	14(127) 5'-gTA 3'	16(133) 5'-gTT 3'	37(196) 5'-AgA 3'	31(178) 5'-gCg 3'
			13(126) 5'-AAg 3'	13(126) 5'-AAg 3'		16(133) 5'-gTT 3'		13(125) 5'-gTC 3'	14(127) 5'-ATA 3'	16(133) 5'-gCT 3'	58(261) 5'-gAg 3'	
			13(126) 5'-AgA 3'						14(127) 5'-ATA 3'	60(265) 5'-AgT 3'		
									16(133) 5'-gTT 3'			
									31(178) 5'-gCg 3'			
3'-primer(s) ³	67(286) 5'-gAg 3'	67(286) 5'-gAT 3'	67(286) 5'-gAT 3'	67(286) 5'-gAA 3'	73(305) 5'-ggC 3'	26(164) 5'-ggT 3'	28(171) 5'-CTC 3'	33(184) 5'-gTg 3'	71(298) 5'-CTC 3'	74(307) 5'-CAg 3'	57(257) 5'-CgA 3'	38(200) 5'-gCg 3'
	67(286) 5'-gAg 3'	67(286) 5'-gAA 3'	67(286) 5'-gAT 3'	67(286) 5'-gAg 3'	73(305) 5'-ggC 3'	67(286) 5'-gAT 3'	70(295) 5'-CTg 3'	58(260) 5'-Cgg 3'	73(305) 5'-ggC 3'	86(344) 5'-CAC 3'	73(305) 5'-ggC 3'	72(303) 5'-gCA 3'
	67(286) 5'-gAT 3'	67(286) 5'-gAA 3'	67(286) 5'-gAT 3'	67(286) 5'-gAg 3'	73(305) 5'-ggC 3'	71(299) 5'-gCT 3'			77(317) 5'-AAT 3'		78(319) 5'-CAC 3'	74(307) 5'-CgC 3'
	70(297) 5'-CTg 3'		70(295) 5'-CTg 3'	70(296) 5'-TgT 3'	73(305) 5'-ggC 3'				78(319) 5'-CgC 3'			
	71(299) 5'-gCg 3'		70(295) 5'-Tg 3'	72(302) 5'-Cgg 3'	73(306) 5'-Tgg 3'				78(319) 5'-CAA 3'			
	73(305) 5'-ggC 3'		70(296) 5'-TCC 3'		74(308) 5'-CCC 3'				78(319) 5'-CAC 3'			
	77(317) 5'-AgT 3'		71(299) 5'-gCg 3'		75(310) 5'-CAA 3'							
	86(344) 5'-CCA 3'		71(299) 5'-gCT 3'		77(317) 5'-AgT 3'							
			72(301) 5'-Cg 3'									
			73(305) 5'-ggC 3'									
			77(317) 5'-AgT 3'									
Well No.	1	2	3	4	5	6	7	8	9	10	11	12



0197

For In Vitro Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

Well No.	13	14	15	16	17	18	19	20	21	22	23
Length of spec.	100	90	220	195	175	85	110	110	90	130	175
PCR product	175	110		225	240	140	145	150	160	210	215
						180	170	180	190		
						240		220	240		
Length of int.	430	430	430	430	430	430	430	430	515	430	430
pos. control ¹											
5'-primer(s) ²	13(125) 5'-gTC 3'	13(124) 5'-Cgg 3'	10(116) 5'-gCT 3'	10(116) 5'-gCT 3'	13(125) 5'-gTC 3'	5(101) 5'-CAA 3'	26(164) 5'-gTA 3'	13(125) 5'-gTC 3'	10(116) 5'-gCT 3'	28(170) 5'-gAT 3'	9(112) 5'-TgC 3'
	16(133) 5'-gTC 3'	16(133) 5'-gTT 3'	12(122) 5'-TAT 3'	12(122) 5'-TAT 3'	13(125) 5'-gTg 3'	37(197) 5'-gTT 3'	34(189) 5'-CAG 3'	34(189) 5'-CAG 3'	10(116) 5'-gCT 3'	28(170) 5'-gAg 3'	13(125) 5'-gTA 3'
	38(200) 5'-CgT 3'		13(125) 5'-gTC 3'	12(123) 5'-ACA 3'	114(429) 5'-CTg 3'	37(197) 5'-gTA 3'	34(189) 5'-CAG 3'	37(196) 5'-AgC 3'	11(119) 5'-gCT 3'	105(401) 5'-AAA 3'	
				13(125) 5'-gTC 3'			34(189) 5'-CCg 3'		38(199) 5'-TCC 3'		
				13(125) 5'-gTg 3'							
				16(133) 5'-gTC 3'							
				16(133) 5'-gTT 3'							
3'-primer(s) ³	58(260) 5'-CCT 3'	28(171) 5'-CTC 3'	70(295) 5'-gTC 3'	67(286) 5'-gAA 3'	58(260) 5'-Cgg 3'	48(230) 5'-CCT 3'	57(257) 5'-CAG 3'	57(257) 5'-CAG 3'	51(239) 5'-CCC 3'	81(328) 5'-gTA 3'	57(256) 5'-gTC 3'
	58(260) 5'-CCT 3'	30(175) 5'-gTg 3'	71(299) 5'-gCT 3'	71(298) 5'-CTC 3'	58(260) 5'-CAG 3'	57(257) 5'-CAG 3'	70(295) 5'-CTg 3'	60(265) 5'-gTg 3'	60(266) 5'-Agg 3'	87(346) 5'-CTC 3'	57(258) 5'-gCg 3'
	58(260) 5'-CCT 3'	38(199) 5'-CAG 3'	71(299) 5'-ACT 3'	71(298) 5'-CgC 3'	181(630) 5'-CTT 3'	71(298) 5'-CgC 3'	70(296) 5'-TCC 3'	70(296) 5'-TCC 3'	77(317) 5'-AAT 3'	87(346) 5'-CTT 3'	57(258) 5'-gCT 3'
	58(261) 5'-TCT 3'		74(307) 5'-CgT 3'					74(307) 5'-CAG 3'		135(490) 5'-gCT 3'	58(260) 5'-CCT 3'
			78(319) 5'-CAC 3'								70(296) 5'-TgT 3'
Well No.	13	14	15	16	17	18	19	20	21	22	23

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 430 or 515 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the longer, 515 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.



0197

For In Vitro Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

CELL LINE VALIDATION SHEET																					
DR low resolution primer set ³																					
					Well ²																
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	
				Prod. No.:	202128501	202128502	202128503	202128504	202128505	202128506	202128507	202128508	202128509	202128510	202128511	202134312	202128513	202128514	202128515	202128516	
	IHWC cell line ¹		DRB1																		
1	9001	SA	*01:01	*04:05	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280	LK707	*15:02		-	-	+	-	-	-	-	-	+	-	-	-	-	-	-	-	-
3	9011	E4181324	*15:02		-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	9275	GU373	*03:01		-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
5	9009	KAS011	*16:01	*08:03	-	-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	
6	9353	SM	*04:07		-	-	-	-	-	-	-	-	+	-	+	-	-	-	-	-	-
7	9020	QBL	*03:01		-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	-
8	9025	DEU	*04:01		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
9	9026	YAR	*04:02		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
10	9107	LKT3	*04:05		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
11	9051	PITOUT	*07:01	*13:01	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	
12	9052	DBB	*07:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
13	9004	JESTHOM	*01:01		+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	9071	OLGA	*08:02		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	+
15	9075	DKB	*09:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
16	9037	SWEIG007	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	+	+
17	9282	CTM3953540	*03:01		-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	+	+
18	9257	32367	*09:01		*11:01	-	-	-	-	-	-	-	-	-	-	+	-	+	-	+	+
19	9038	BM16	*12:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	-
20	9059	SLE005	*13:02		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+	+
21	9064	AMALA	*14:02	*14:54	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	
22	9056	KOSE	*13:02		-	-	-	-	-	+	-	-	-	-	-	-	-	-	-	+	+
23	9124	IHL	*08:03		*14:14	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
24	9035	JBUSH	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	+	+
25	9049	IBW9	*07:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
26	9285	WT49	*03:01		-	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-
27	9191	CH1007	*04:05		*10:01	-	-	-	-	-	-	-	+	-	-	-	+	-	-	-	-
28	9320	BEL5GB	*04:16		*07:01	-	-	-	-	-	-	-	+	+	-	-	-	-	-	-	-
29	9050	MOU	*07:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
30	9021	RSH	*03:02		-	-	-	-	+	-	+	-	-	-	-	-	-	-	-	-	-
31	9019	DUCAF	*03:01	*04:06	-	-	-	-	+	+	-	-	-	-	-	-	-	-	-	-	
32	9297	HAG	*13:03		-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	+	-
33	9098	MT14B	*04:04		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
34	9104	DHIF	*11:01		-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	+	+
35	9302	SSTO	*04:03		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
36	9024	KT17	*04:03		-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-
37	9065	HHKB	*13:01		-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	+	+
38	9099	LZL	*14:02		-	-	-	-	-	-	-	+	-	-	-	-	-	-	-	-	-
39	9315	CML	*03:01		*04:01	-	-	-	-	+	+	-	+	-	-	-	-	-	-	-	-
40	9134	WHONP199	*07:01		*09:01	-	-	-	-	-	-	-	-	+	-	-	+	-	-	-	-
41	9055	H0301	*13:02	*12:01	-	-	-	-	-	+	-	-	-	-	-	-	-	-	+	+	
42	9066	TAB089	*08:03		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-
43	9076	T7526	*09:01		-	-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	-
44	9057	TEM	*14:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
45	9239	SHJO	*07:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	-	-
46	9013	SCHU	*15:01		-	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
47	9045	TUBO	*11:04		-	-	-	-	-	-	-	-	-	-	-	-	-	+	+	+	+
48	9303	TER-ND	*01:03		-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-



0197

For In Vitro Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

CELL LINE VALIDATION SHEET												
DR low resolution primer set ³												
					Prod. No.:	Well ²						
						17	18	19	20	21	22	23
						202128517	202128518	202128519	202128520	202128529	202128530	202128531
	IHCW cell line ¹		DRB1									
1	9001	SA	*01:01			-	-	-	-	-	-	-
2	9280	LK707	*15:02	*04:05		-	-	-	-	-	+	+
3	9011	E4181324	*15:02			-	-	-	-	-	-	+
4	9275	GU373	*03:01			+	-	-	-	+	-	-
5	9009	KAS011	*16:01			-	-	-	-	-	-	+
6	9353	SM	*04:07	*08:03		-	-	-	-	-	+	-
7	9020	QBL	*03:01			+	-	-	-	+	-	-
8	9025	DEU	*04:01			-	-	-	-	-	+	-
9	9026	YAR	*04:02			-	-	-	-	-	+	-
10	9107	LKT3	*04:05			-	-	-	-	-	+	-
11	9051	PITOUT	*07:01			-	-	-	-	-	+	-
12	9052	DBB	*07:01			-	+	-	-	-	+	-
13	9004	JESTHOM	*01:01			-	-	-	-	-	-	-
14	9071	OLGA	*08:02			-	-	-	-	-	-	-
15	9075	DKB	*09:01			-	-	+	-	-	+	-
16	9037	SWEIG007	*11:01			-	-	-	-	+	-	-
17	9282	CTM3953540	*03:01	*13:01		+	-	-	-	+	-	-
18	9257	32367	*09:01	*11:01		-	-	+	-	+	+	-
19	9038	BM16	*12:01			-	-	-	-	+	-	-
20	9059	SLE005	*13:02			+	-	-	-	+	-	-
21	9064	AMALA	*14:02			+	-	+	-	+	-	-
22	9056	KOSE	*13:02	*14:54		+	+	+	+	+	-	-
23	9124	IHL	*08:03	*14:14		+	-	+	+	+	-	-
24	9035	JBUSH	*11:01			-	-	-	-	+	-	-
25	9049	IBW9	*07:01			-	-	-	-	-	+	-
26	9285	WT49	*03:01			+	-	-	-	+	-	-
27	9191	CH1007	*04:05	*10:01		-	-	-	-	-	+	-
28	9320	BEL5GB	*04:16	*07:01		-	-	-	-	-	+	-
29	9050	MOU	*07:01			-	-	-	-	-	+	-
30	9021	RSH	*03:02			+	-	-	-	+	-	-
31	9019	DUCAF	*03:01			+	-	-	-	+	-	-
32	9297	HAG	*13:03			+	-	-	-	+	-	-
33	9098	MT14B	*04:04			-	-	-	-	-	+	-
34	9104	DHIF	*11:01			-	-	-	-	+	-	-
35	9302	SSTO	*04:03			-	-	-	-	-	+	-
36	9024	KT17	*04:03	*04:06		-	-	-	-	-	+	-
37	9065	HHKB	*13:01			+	-	-	-	+	-	-
38	9099	LZL	*14:02			+	-	+	-	+	-	-
39	9315	CML	*03:01	*04:01		+	-	-	-	+	+	-
40	9134	WHONP199	*07:01	*09:01		-	-	+	-	-	+	-
41	9055	H0301	*13:02			+	-	-	-	+	-	-
42	9066	TAB089	*08:03			-	-	-	-	-	-	-
43	9076	T7526	*09:01			-	-	+	-	-	+	-
44	9057	TEM	*14:01			+	+	+	+	+	-	-
45	9239	SHJO	*07:01			-	-	-	-	-	+	-
46	9013	SCHU	*15:01			-	-	-	-	-	-	+
47	9045	TUBO	*11:04	*12:01		-	-	-	-	+	-	-
48	9303	TER-ND	*01:03			-	-	-	-	-	-	-



0197

For In Vitro Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

¹The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

²The DRB4*01:03:01:02N allele is amplified by primer mix 18 in the 9052 (DBB) cell line.

³The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

In primer solutions 9, 11, 15 and 18 one or more 5'- and/or 3'-primers were tested by separately adding one 3'-primer, or one 5'-primer respectively.

In primer solutions 4, 6, 12 and 16 one or more 5'-primers were tested by separately adding one 3'-primer.

In primer solutions 1, to 3, 5 and 20 one or more 3'-primers were tested by separately adding one 5'-primer.

In primer solutions 1, 3, 4, 8 to 10, 13 to 17, 19, 20 and 22 one or more 5'-primers were not possible to be tested.

In primer solutions 1 to 6, 9, 13, 15, 22 and 23 one or more 3'-primers were not possible to be tested.



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00

101.103.48/12 – including *Taq* pol., IFU-01
101.103.48u/12u – without *Taq* pol., IFU-02

Visit <https://labproducts.caredx.com> for
“Instructions for Use” (IFU)

Lot No.: **9L6**

Lot-specific information

ADDRESSES:

Manufacturer:

CareDx AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

Fax: +46-8-717 88 18

E-mail: orders-se@caredx.com

Web page: <https://labproducts.caredx.com/>

CareDx Lab Solutions Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-653-78171

Fax: 610-344-7989

E-mail: orders-us@caredx.com

Web page: <https://labproducts.caredx.com/>

For information on CareDx distributors worldwide, contact **CareDx AB**.



0197

For *In Vitro* Diagnostic Use
MA123 v01 SSP PI Template
Date: August 2021, Rev. No: 00